MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/jdv.13682

Медицинская библиотека · Journal of the European Academy of Dermatology and Venereology : JEADV · 2016

Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.

Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García F-J, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo J-L, Alsina M, López-Estebaranz J-L, Ferrán M, Torrado R, Carrascosa J-M, Llamas M, Rivera R, Jiménez-Puya R, García-Doval I, BIOBADADERM Study Group

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Few reported studies compare drug survival in moderate-to-severe psoriasis vulgaris.

OBJECTIVES

To describe and compare drug survival of systemic drugs, including biologic agents (infliximab, etanercept, adalimumab and ustekinumab) and classical drugs (acitretin, ciclosporin and methotrexate) in moderate-to-severe psoriasis.

METHODS

This was a multicenter, prospective, cohort study of patients receiving systemic therapies between 2008 and 2013 in 12 hospitals in Spain. Baseline data and drug discontinuation were collected. Drug survival is presented using Kaplan-Meier survival curves. We compared adjusted risk ratios of serious adverse events (AEs) with results of survival analysis for AEs.

RESULTS

A total of 1956 patients were included for analysis (1240 exposed to biologics during follow-up and 1076 to classic therapies). Median follow-up time was 3.3 years (0.0-5.1 years). There were 2209 discontinuations out of 3640 therapy cycles started. The main reason for discontinuation was lack of efficacy (36.4%) and remission (27.2%). Biologics showed a higher drug survival than classics and the pattern of survival results for all outcomes (positive or negative) were very similar. Adjusted risk ratios of serious AEs did not agree with results of survival analysis.

LIMITATIONS: A limitation is that this is an observational study with potential selection bias.

CONCLUSION

Survival as a proxy measure of drug safety in psoriasis is inadequate.

Для цитирования: Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García F-J, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo J-L, Alsina M, López-Estebaranz J-L, Ferrán M, Torrado R, Carrascosa J-M, Llamas M, Rivera R, Jiménez-Puya R, García-Doval I, BIOBADADERM Study Group. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.. Journal of the European Academy of Dermatology and Venereology : JEADV. 2016. DOI: 10.1111/jdv.13682.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.